ReviewZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2022
[Proteomic-driven precision medicine research in hepatocellular carcinoma].
Review in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Proteomics is the study of proteins-the direct executor of life activities. Protein plays a vital role in the development and growth of human body and the genesis and development of diseases. It is the most widely used clinical marker type and the direct drug target. In recent years, the advance of proteomic core technology with chromatography and mass spectrometry has promoted the rapid development in the depth and breadth of proteomic research, and its application in the large cohort of hepatocellular carcinoma opens a new era of proteomics-driven precision medicine (PDPM). This review highlights the proteomic research in new techniques, directions and discoveries of hepatocellular carcinoma research in recent years, providing new ideas and references for clinicians to understand proteomics, and to use proteomics to assist in the diagnosis of diseases and the development of personalized therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.